Cargando…
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma
The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less than 30% of patients with metastatic or recurrent disease survive despite aggressive combinations of chemotherapy, radiation and surgery. To identify new therapeutic options, we employed a multi-pronged approach using...
Autores principales: | Pessetto, Ziyan Y., Chen, Bin, Alturkmani, Hani, Hyter, Stephen, Flynn, Colleen A., Baltezor, Michael, Ma, Yan, Rosenthal, Howard G., Neville, Kathleen A., Weir, Scott J., Butte, Atul J., Godwin, Andrew K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354814/ https://www.ncbi.nlm.nih.gov/pubmed/27863422 http://dx.doi.org/10.18632/oncotarget.13385 |
Ejemplares similares
-
Developing a genetic signature to predict drug response in ovarian cancer
por: Hyter, Stephen, et al.
Publicado: (2017) -
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020) -
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers
por: Samuel, Glenson, et al.
Publicado: (2020) -
Cutaneous Ewing Sarcoma and Ewing Sarcoma of the Bone: Distinct Diseases
por: Tavakkoli, Montreh, et al.
Publicado: (2018) -
The Biology of Ewing Sarcoma
por: Ross, Keir A., et al.
Publicado: (2013)